Home › Trial NCT06781125
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
- Trial IDNCT06781125
- StatusNot Yet Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorImmorna Biotherapeutics, Inc.
- Enrollment72
- Start date2026-03-18
- ConditionsMalignant Solid Tumors
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.